Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck KGaA's shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term. The life ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

German pharma and technology giant Merck has announced a €5 million (£4.2m) investment in Scotland that will create further jobs at its diagnostics and blood typing facility in Livingston.

In this article, we will look at where Merck & Co. Inc. (NYSE:MRK) ranks among the most undervalued quality stocks to buy according to analysts. Despite global uncertainties, the US economy is ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Merck’s new €290m biosafety testing facility in Rockville features advanced testing capabilities. Credit: Merck/Business Wire. Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the February 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a perioperative regimen in certain patients with head and neck cancer ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. After a pivotal trial failure two years ago in unresected locally advanced head and neck ...

Oct 7 (Reuters) - Merck (MRK.N), opens new tab is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off ...

Merck is a blue-chip stock, but that doesn't mean I want to own it here. The risk of loss is too high, based on several metrics I track. Technical indicators and charts suggest high risk for MRK ...